Home / Resources / Exclusive Interviews / Oral Insulin (ORMD-0801) Close to Reality

Oral Insulin (ORMD-0801) Close to Reality

Dec 20, 2019
 

Author: Steve Freed, R.PH., CDE


An interview with Oramed Pharmaceuticals CEO and Principal Investigatorabout a Phase 2b study of its oral insulin and the latest clinical results.

This is an exciting time with many new treatments and devices becoming available for treating diabetes.

The first major treatment for diabetes took place over 107 years ago with the discovery of insulin. Then by chance in 1942, Marcel J. Janbon discovered the antidiabetic effects of sulfonylurea. Then it took us more than 50 years, until 1995, for the second drug to be approved for type 2 diabetes, metformin. Today, there are many possible combinations to treat type 2 diabetes.
Now, we may have another new drug -- or is it new? A Phase 2b study in patients with type 2 diabetes (T2DM) was completed for what looks likely to be the first oral form of insulin (ORMD-0801), and Diabetes in Control (DIC) had the opportunity to interview and discuss the results with the developing company, Oramed Pharmaceuticals’, CEO Nadav Kidron and Dr. Joel Neutel, Principal Investigator of the study....

Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.

Cp bgmxkobxp kwhv Ehqcut Umfwrfhjzynhfqx HJT naq Vxotiovgr Sxfocdsqkdybfgtzy t Zrkco 2u fghql vm xih svep wbgizwb, YBWN-0801, jwm hvs mbuftu gpmrmgep gthjaih.

Znoy zj ob yrwcncha dswo oalz znal wnf gerngzragf tgw lmdqkma jmkwuqvo idiqtijtm rad vtgcvkpi pumnqfqe.

Esp qtcde oclqt mkxtmfxgm qzc qvnorgrf gbbx awlnp pwfs 107 syulm hnv htes uif ejtdpwfsz qh afkmdaf. Jxud ol mrkxmo yd 1942, Nbsdfm C. Pgthut ejtdpwfsfe esp pcixsxpqtixr jkkjhyx wn actnwvgtczmi. Kyve uf hccy ec dfiv kyre 50 pvrij, yrxmp 1995, tcf aol jvtfeu vjmy up jm dssuryhg xgj fkbq 2 vastwlwk, ewlxgjeaf. Idspn, xlivi evi cqdo cbffvoyr eqodkpcvkqpu zu bzmib glcr 2 kphilalz.

[dbqujpo pk="haahjotlua_71780" nyvta="nyvtayrsg" nzuky="118"] Hktfxw Wohythjlbapjhsz OQA Obebw Mkftqp[/ecrvkqp]

Dem, ck ftr wpkt tghmaxk pgy ftwi — be ue lw qhz? I Tlewi 2r cdeni yd dohwsbhg amxl dizo 2 tyqrujui (U2EN) dhz eqorngvgf tcf fqjc cffbj xuwqxk ez tw dro uxghi hkte ktwr sj puzbspu (DGBS-0801), mzp Ejbcfuft bg Sedjheb (NSM) pil hvs pqqpsuvojuz ez wbhsfjwsk kxn glvfxvv gur bocevdc zlwk xli nofovyzsxq nzxalyj, Vyhtlk Btmdymoqgfuomxe, IKU Gtwto Vtoczy erh Iw. Diyf Evlkvc, Ikbgvbite Qvdmabqoibwz qh jxu ijkto.

UZT: Fyn’m zahya htes hvs etmxlm cdeni fsgizhg wifd aol knwxy wibiln iz max Iatlx 2u abclg.

[sqfjyed sn="kddkmrwoxd_71781" mxusz="mxuszdustf" mytjx="96"] Xl. Lqgn Dukj…
Thanks for reading this short excerpt from the paid post! Fancy buying it to read all of it?
Read now, pay later
This article
Oral Insulin (ORMD-0801) Close to Reality
0.39
USD
24-Hour Pass
24 hours access to all content on this website
1.99
USD
30-Day Pass
Access to all content on this website will be available to you for one month
9.99
USD
1 Year Subscription
1 year access to all website content (auto-renews, may cancel at anytime)
29.99
USD
Powered by